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Drosophila screen connects nuclear 
transport genes to DPR pathology 
in c9ALS/FTD
Steven Boeynaems1,2,*, Elke Bogaert1,2,*, Emiel Michiels1,2, Ilse Gijselinck3,4, Anne Sieben3,4,5, 
Ana Jovičić6, Greet De Baets7,8, Wendy Scheveneels1,2, Jolien Steyaert1,2, Ivy Cuijt3,4, 
Kevin J. Verstrepen9,10, Patrick Callaerts11,12, Frederic Rousseau7,8, Joost Schymkowitz7,8, 
Marc Cruts3,4, Christine Van Broeckhoven3,4, Philip Van Damme1,2,13, Aaron D. Gitler6, 
Wim Robberecht1,2,13 & Ludo Van Den Bosch1,2
Hexanucleotide repeat expansions in C9orf72 are the most common cause of amyotrophic lateral 
sclerosis (ALS) and frontotemporal degeneration (FTD) (c9ALS/FTD). Unconventional translation 
of these repeats produces dipeptide repeat proteins (DPRs) that may cause neurodegeneration. We 
performed a modifier screen in Drosophila and discovered a critical role for importins and exportins, 
Ran-GTP cycle regulators, nuclear pore components, and arginine methylases in mediating DPR 
toxicity. These findings provide evidence for an important role for nucleocytoplasmic transport in the 
pathogenic mechanism of c9ALS/FTD.
C9orf72 hexanucleotide repeat expansions are the most common genetic cause of ALS and FTD (c9ALS/FTD)1,2. 
Despite the importance of these mutations, the underlying pathogenic mechanisms remain elusive. Three main 
hypotheses have been proposed to explain how C9orf72 mutations could cause disease: haploinsufficiency 
due to lowered transcription of the C9orf72 gene, RNA toxicity resulting from the sequestration of essential 
RNA-binding proteins by sense and antisense repeat RNA foci that accumulate in the nucleus and cytoplasm, 
and repeat associated non-ATG (RAN) translation of sense and antisense RNA3. This unconventional form of 
translation results in the generation of distinct aggregation-prone dipeptide repeat proteins (DPRs). These DPRs 
are found in the hallmark p62-positive, TDP-43 negative inclusions seen in c9FTD/ALS patients4–6. Mounting 
evidence points to a direct role of these DPRs in neurodegeneration7–10 but the mechanism by which these DPRs 
cause toxicity remains unresolved and of intense interest. Defining the cellular mechanisms of DPR toxicity is 
necessary to understand the disease pathogenesis and may reveal new targets for therapeutic intervention.
We used Drosophila to investigate the mechanisms by which C9orf72 DPRs cause toxicity and neurodegenera-
tion. To focus specifically on DPR toxicity, we had to experimentally separate the generation of the DPRs from the 
presence of repeat RNA. We generated expression constructs allowing ATG-mediated expression of a single DPR 
and codon-optimized these constructs to reduce the formation of stable repeat RNA secondary structures. Hence, 
these constructs allow us to attribute observed phenotypes solely to expression of one DPR, and rule out any con-
founding RNA toxicity or RAN translation. We generated fly lines expressing 50 repeats of four of the five possible 
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DPRs (GA, GR, PA and PR). Consistent with recent reports8–10, we found that expression of the arginine-rich 
DPRs, GR and PR, strongly reduced survival in flies expressing these DPRs in adult flies either ubiquitously or 
motor neuron-specific (Fig. S1). Thus, this Drosophila model recapitulates robust C9orf72 DPR toxicity, providing 
a tractable system to identify and characterize toxicity modifier genes.
Jovičić et al. reported results from two unbiased genome wide screens in yeast for suppressors and enhancers 
of PR toxicity11. These two screens identified a striking number of modifier genes involved in nucleocytoplasmic 
transport. These modifiers include karyopherins, nuclear pore complex components, and enzymes involved in 
generating the Ran-GTP gradient that drives nuclear transport. Since the general principles and key molecules 
of nucleocytoplasmic transport are highly-conserved from yeast to flies to humans12, we sought to validate these 
results in an animal model and to test the hypothesis that genes involved in nuclear transport could also modify 
C9orf72 DPR toxicity in vivo. We therefore performed a targeted RNAi screen in Drosophila. To facilitate the rapid 
identification of modifiers of DPR toxicity, we used eye degeneration as a readout. We directed expression of a 
single copy of the 25 PR repeat construct to the fly eye. This caused a moderate degenerative phenotype (Fig. 1a), 
providing the ability to identify both suppressors and enhancers.
To focus on nucleocytoplasmic transport and related processes, we compiled a library of 121 independent 
RNAi lines targeting 55 fly genes (Table S1), encoding nuclear pore complex proteins, importins, exportins, reg-
ulators of the Ran-GTP cycle, and arginine methylases, which affect protein localization by modulating NLS 
sequences13. We expressed each RNAi together with the PR25 construct and scored for the ability to enhance 
or suppress the phenotype (Fig. 1b, Fig. S2). We identified 15 enhancers and 4 suppressors of the PR25 eye 
Figure 1. Genes implicated in nuclear transport are potent modifiers of PR toxicity in Drosophila.  
(a) Expression of a PR25 construct in the fly eye induces a moderate degenerative eye phenotype compared 
to the eyes of non-affected PA-expressing flies or severely affected flies expressing two copies of the PR25 
transgene. (b) Setup of RNAi screen for PR25 modifiers. (c) Knockdown of four karyopherins (Trn, Fs(2)Ket, 
Kap-alpha3 and Ranbp11) strongly enhanced PR toxicity. (d) Knockdown of RanGTP cycle regulators Rangap 
and Rcc1 both enhance eye degeneration. (e) Knockdown of some nuclear pore complex components (Nup50, 
Nup107 and Nup154) suppressed degeneration others (Nup44A, Nup62, Nup93-1) enhanced the phenotype. 
(a,e) show males, (c,d) females.
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phenotype (Table 1, Table S4). Importantly, the RNAi lines did not cause a degenerative eye phenotype in a wild 
type background (Fig. S3a) and the RNAi lines that suppressed PR toxicity did not affect PR expression (Fig. S3b).
Knockdown of four members of the importin family (Ranbp11, Kap-alpha3, Fs(2)Ket and Trn), which 
mediate nuclear import of cargo proteins, caused striking enhancement of the PR25 eye phenotype (Fig. 1c). 
Knockdown of another importin, CG32165, mildly suppressed toxicity and knockdown of the exportin emb 
enhanced PR toxicity. We also identified the two regulators of the Ran-GTP cycle (Rcc1 and RanGap) as modifiers 
of PR25 toxicity (Fig. 1d). Subunits of the nuclear pore complex were suppressors (Nup50, Nup107 and Nup154) 
and enhancers (Mtor, Nup44A, Nup62 and Nup93-1) (Fig. 1e). Finally, knockdown of four different arginine 
methyltransferases (Art1, Art6, Art7 and Fbx011) enhanced PR toxicity.
The strongest enhancer of PR-mediated neurodegeneration was knockdown of Trn (Fig. 2a, Fig. S4), the 
fly ortholog of TNPO1, encoding transportin 1. Of notice, the yeast TNPO1 homolog Kap104 was one of the 
strongest suppressors of PR toxicity in yeast11. Interestingly, transportin 1 has been connected to another form of 
ALS/FTD, namely related to FUS13,14. ALS-causing mutations in FUS/TLS impair transportin-mediated nuclear 
import, resulting in FUS cytoplasmic accumulation and aggregation15 and in FTD cases with FUS pathology 
transportin 1 is mislocalized to cytoplasmic FUS aggregates14. To determine whether PR could directly act on 
transportin 1 function, we performed computational docking simulations (Fig. 2b) and predicted that PR can 
interact with transportin 1. This suggested that PR might compete for endogenous transportin 1 cargoes. To test 
this hypothesis, we analyzed the effect of PR expression on the localization of a well-characterized transportin 1 
cargo, the neuronal RNA-binding protein Elav. We observed increased cytoplasmic localization and decreased 
nuclear staining of Elav in flies expressing PR (Fig. 2c). Moreover, Elav mislocalization increased further upon 
Trn knockdown (Fig. 2c). Consistent with previous reports, we also observed the cytoplasmic aggregation of the 
transportin 1 cargo hnRNPA3 in human c9FTD (Fig. 2d, Table S2). These findings suggest a potential role of 
transportin 1 in the pathogenesis of c9ALS/FTD.
Finally, knockdown of four out of ten arginine methyltransferase genes enhanced PR toxicity in Drosophila 
(Table 1, Fig. 2e). One of these, PRMT1, has been previously implicated in ALS caused by FUS/TLS mutations13,16. 
To determine whether this enzyme could directly affect DPR toxicity, we performed colocalization experiments 
in cell lines. PRMT1 colocalized with both GR and PR (Fig. 2f, Fig. S5). We subsequently tested several commer-
cially available antibodies to detect methylation. One of them, ASYM24, was able to detect asymmetric arginine 
dimethylation of GR, but not PR. This was not surprising since this antibody was originally raised against a 
peptide showing strong sequence similarity with GR, but not PR (Fig. S5). Using this antibody we found GR 
accumulations to be methylated in transfected cells, but also an association of GR with other methylated proteins, 
as determined by super resolution microscopy (Fig. 2g). To validate this new aspect of DPR pathology in humans, 
we performed immunostaining on c9FTD brain samples and detected abundant methylated inclusions (Fig. 2h, 
Table S3). These results implicate arginine methyltransferases to c9ALS/FTD pathogenesis.
Fly gene E/S Human gene
Nuclear Pore Complex
 Mtor E TPR
 Nup44A E SEH1
 Nup50 S NUP50
 Nup62 E NUP62
 Nup93-1 E NUP93
 Nup107 S NUP107
 Nup154 S NUP155
Importins/Exportins
 CG32165 S IPO4
 Fs(2)Ket E KPNB1
 Kap-alpha3* E KPNA3, KPNA4
 Ranbp11* E IPO11
 Trn* E TNPO1
 emb E XPO1
Ran-GTP regulators
 RanGap E RANGAP1
 Rcc1* E RCC1
Arginine methytransferases
 Art1 E PRMT1
 Art6 E —
 Art7 E PRMT7
 Fbx011 E FBX010, FBX011
Table 1. Modifiers of PR25-mediated eye degeneration uncovered in a targeted RNAi screen. *Indicates 
genes which were independently discovered in genome-wide yeast screens11. S = suppressor; E = enhancer.
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Figure 2. Transportin-1 and arginine methylation are directly implicated in DPR models and C9 patients. 
(a) Trn knockdown potently enhanced the PR-induced degenerative eye phenotype. Females are shown. (b) 
Computational conformational docking predictions predict that PR can fit the transportin-1 binding pocket. 
Positive arginine side chains of PR (red) interact with the negative side chains (blue) of the binding pocket. (c) Elav 
is mislocalized to the cytoplasm in PR expressing flies. Mislocalization is exacerbated upon Trn RNAi knockdown. 
Arrowheads indicate cytoplasmic staining. Scale bar indicates 5 μ m. (d) hnRNPA3 is mislocalized in c9FTD cases 
(arrowheads) but not in disease-negative controls. Picture shows dentate gyrus. Scale bar indicates 10 μ m. (e) Art1 
knockdown enhances the PR-induced eye phenotype. Males are shown. (f) PR colocalizes with PRMT1 upon 
cotransfection in HeLa cells, as determined by super resolution microscopy (SIM). (g) GR staining associates 
with (arrowheads) and partially colocalizes with (arrow) ASYM24 staining in transfected neuroblastoma cells, as 
determined by SIM. Scale bars indicate 10 μ m. (h) Immunostaining with ASYM24 detects methylated pathological 
aggregates (arrowheads) in dentate gyrus of c9FTD patient samples but not in controls. Scale bar indicates 10 μ m.
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In summary, we performed a targeted genetic modifier screen in Drosophila and confirm results obtained in 
two yeast screens11. Both studies consolidate DPRs as major contributing factors to c9 toxicity and point at a role 
for nucleocytoplasmic transport in this toxicity. Strikingly, the homologs of the strongest genes from the yeast 
screens were potent modifiers of DPR toxicity in Drosophila. Not only does this validate the effectiveness of mod-
ifier genes discovered in yeast in an animal model, it also suggests that DPR pathologies associated with c9ALS/
FTD disrupt a highly conserved facet of cell biology.
Depletion of RNA-binding proteins (RBPs) such as TDP-43, FUS and others from the nucleus, and cytoplas-
mic accumulation are pathognomonic features of both ALS and FTD17, including c9ALS/FTD18–20. The upstream 
triggers of this nuclear depletion and subsequent cytoplasmic aggregation are unresolved. Our results help to 
explain how disturbances in nucleocytoplasmic trafficking caused by C9orf72 repeat expansion pathology could 
trigger RBP mislocalization and subsequent aggregation. Most RBPs are tightly regulated in their cellular localiza-
tion, and shuttle in a strictly controlled manner between nucleus and cytoplasm. Impairments, even subtle, to the 
nuclear pore, karyopherins, or the Ran-GTP gradient, could perturb this sensitive equilibrium providing a first 
hit that would eventually lead to aberrant accumulation of RBPs in the cytoplasm, setting off a cascade of aggrega-
tion and sequestration of these proteins into pathological inclusions. Interestingly, preliminary histopathological 
studies suggest that C9orf72 DPR accumulation predates TDP-43 pathology in FTLD patients harboring C9orf72 
mutations21,22.
DPR pathology is one way that C9orf72 mutations might contribute to disease pathogenesis. First of all, a role 
for C9orf72 loss of function, owing to decreased expression of C9orf72, has not been conclusively ruled in or out. 
A recent report potentially even links the C9ORF72 protein to nuclear transport23. Secondly, sense and antisense 
RNA transcripts produced from the GGGGCC hexanucleotide repeat expansion accumulate in the nucleus and 
cytoplasm of mutation carriers3 and could cause disease by an RNA toxicity mechanism (e.g., by sequestering 
important regulatory proteins like splicing factors and other RNA-binding proteins). Two recent studies report 
the results from genetic screens similar to ours using GGGGCC repeat fly models24,25. Compellingly, these studies 
also identify nuclear transport as a key pathogenic factor in these fly models, hereby suggesting that the repeat 
RNA itself could also directly perturb nuclear transport. However, two other reports have ruled out RNA toxicity 
in flies, at least at the short lengths used in the current models, and attribute all observed phenotypes to DPR tox-
icity10,26. Moreover, since we identify similar modifiers using a pure DPR model, this raises the question whether 
the repeat RNA itself is truly involved in the observed nuclear transport defects.
The three potential pathogenic mechanisms are not mutually exclusive and future studies will be required 
to disentangle the relative contributions of DPR proteotoxicity, RNA toxicity, and C9orf72 loss of function to 
c9FTD/ALS. Moreover, why the same C9orf72 mutations cause dementia in some patients, ALS in others patients, 
and ALS/FTD in yet others, even within the same family, is unresolved and might be influenced by modifier 
genes. A better understanding of the mechanisms by which C9orf72 hexanucleotide repeats cause disease will 
allow the identification of novel targets for therapeutic intervention.
Material & Methods
Plasmids and strains. FLAG-tagged DPR expression constructs were designed by manually codon-opti-
mizing the sequence, and using Mfold software27 to control for any persistent stable secondary structures (Fig. 
S6, Table S5). DNA constructs were synthesized by Genscript (Piscataway, USA). DPR constructs were subcloned 
in CMV6 entry plasmids (Origene) for expression in mammalian cells. Subcloning to the pUAST-attB backbone 
allowed the generation of transgenic fly lines by targeted insertion into the 62E1 attP locus on the third chromo-
some (GenetiVision, USA). The PRMT1-EGFP construct was a kind gift of Dr. F. Fackelmayer (Laboratory for 
Epigenetics and Chromosome Biology, Ioannina, Greece).
Lifespan assay. Lifespan experiments were performed using, the TARGET system28. The tub-Gal4 or 
the D42-Gal4 driver was combined with a ubiquitously expressed temperature-sensitive Gal80 inhibitor 
(tub-Gal80ts). Fly crosses were grown at 18 °C and adult progeny of carrying the tub-Gal4 or the D42-Gal4 and 
tub-Gal80 chromosomes and the UAS-DPR responder gene were shifted to 29 °C to allow expression of the trans-
genes. Females were collected within 24 hr of eclosion and grouped into batches of 10 flies per food vial. Fresh 
food vials were provided every 2–3 days.
Dot blot analysis. The GMR PR25 screening stock was crossed with the four suppressor lines and offspring 
was collected. 30 flies per condition were decapitated and fly heads were homogenized in 30 μ l of RIPA buffer. 
15 μ l of homogenate was spotted onto a nitrocellulose membrane (Amersham) and air dried. Loading controls 
were visualized using Coomassie staining (Life Technologies). Membranes were blocked in 5% milk powder 
(Bio-Rad) in TBS-T buffer and probed with a custom rabbit PR antibody (Thermo Scientific). HRP-labeled anti 
rabit secondary antibody was used (Dako) and membranes were imaged using chemiluminescence (Pierce) and 
an Image Quant Las 4000 imaging station (GE).
Cell culture and transfection. HeLa cells (ATCC) were cultured in high glucose DMEM (Invitrogen) sup-
plemented with 10% fetal bovine serum (Greiner), 4 mM Glutamax (Invitrogen), penicillin (100 U/mL), strep-
tomycin (100 μ g/mL) and non-essencial amino acids (1%). Neuroblastoma cells (SH-SY5Y cells, ATCC) were 
cultured in high glucose DMEM/F12 (Invitrogen) supplemented with 10% fetal bovine serum (Greiner), 4 mM 
Glutamax (Invitrogen), penicillin (100 U/mL), streptomycin (100 μ g/mL) and non-essencial amino acids (1%). 
Cells were grown at 37 °C in a humidified atmosphere with 7% CO2. Cells were transiently transfected using 
Lipofectamine 3000 (Invitrogen) according to manufacturer’s instructions.
Immunofluorescence, immunohistochemistry and microscopy. Fly brains were dissected and fixed 
in 4% formaldehyde in PBS. Cells were fixed 24 h after transfection in 4% formaldehyde in PBS and stained 
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according standard protocols. Following antibodies were used: anti-FLAG (F3165, Sigma), rabbit anti-FLAG 
(#2368S, Cell Signaling), rabbit anti-PR (custom generated antibody, Thermo Scientific), ASYM24 (07-414, 
Millipore), rat anti-Elav (7E8A10, Developmental Studies Hybridoma Bank). AlexaFluor 555 and AlexaFluor 
488 secondary antibodies (Life Technologies) were used. Nuclei were visualized using Hoechst counterstaining 
(Sigma). Slides were mounted using ProLong Gold antifade reagent (Life Technologies).
The  ASYM24 ant ib o dy  was  or ig ina l ly  generated  against  an  inter r upted  GR rep eat 
(KGRGRGRGRGPPPPPRGRGRGRG). This antigen shows strong sequence similarity with GR and hence was 
able to detect GR methylation, but not PR methylation. The antibody was specific for methylated residues as 
staining was abolished using a general methylation inhibitor Adox.
Confocal images were obtained using a Zeiss LSM 510 Meta NLO confocal microscope and SIM microscopy 
was performed using a Zeiss Elyra S.1 microscope (Carl Zeiss, Germany). SIM calculations were performed 
using default settings. Images were analyzed, formatted and quantified with FIJI and ImageJ software. For all 
experiments representative photographs are shown from multiple wells from transfections with at least two cell 
passages, or from multiple fly brains.
Autopsied brains of six C9orf72 carriers and two non-disease controls were obtained using informed consents 
and protocols that were approved by the Ethical Committee of University of Antwerp and Antwerp University 
Hospital and stored in the Antwerp Biobank of the Institute Born-Bunge. Methods were carried out in accord-
ance with the approved guidelines. Clinical data are shown in Table S6. After a fixation period of 8 to 16 weeks 
in 10% buffered formalin, 5 μ m slices were cut from following regions: frontal cortex, hippocampus with dentate 
gyrus and parahippocampal gyrus, cerebellar cortex, medulla oblongata. Sections were deparaffinized, rehydrated 
and pretreated with citric acid 0.1 M. Immunohistochemical analysis was performed with anti-hnRNPA3 anti-
body (AV41195, Sigma) and ASYM24 antibody (07-414, Millipore). Sections were counterstained with hema-
toxylin and images were taken on an Axioskop 50 light microscope (Zeiss) equipped with a CCD UC30 camera 
(Olympus Inc.).
RNAi modifier screen. To identify modifiers of our PR25 eye phenotype we crossed 121 RNAi lines 
with our screening stock. The RNAi lines were obtained from VDRC or Bloomington Drosophila stock center 
(USA). For each cross the collected offspring was divided by sex, and the genotypes were counted according to 
the balancers. The offspring ratio was determined by (expected offspring/counted offspring). For each sex we 
subsequently assigned an average color using following scoring scale (white = 1, yellow = 2, yellow-orange = 3, 
orange-yellow = 4, orange = 5, orange-red = 6, red-orange = 7, red = 8). Afterwards, each fly was individually 
scored for the presence of necrotic spots using following scoring scale (not affected = 0, mild = 1, medium = 2, 
heavy = 3, extreme = 4). We crossed each line at least two independent times. After compiling all data, two 
researchers assigned independently a status to each RNAi line (no effect, enhancer or suppressor) as compared to 
a cross of the screening stock to the RNAi w1118 background. Only whenever a gene was represented by at least 
two RNAi lines showing a similar effect on the phenotype, the gene was classified as an enhancer or suppressor. 
When shown, statistics were carried out using Prism software.
RNAi lines did not present with a degenerative eye phenotype by themselves. Two RNAi lines used had a 
‘greasy’ eye phenotype reminiscent of mitochondrial eye phenotypes. These lines indeed had reported off tar-
get effects on genes involved in eye development: i.e. v105181 off target CG8085, v36103 off target CG4389. 
Importantly, both these hits were verified by independent RNAi lines without this ‘greasy’ eye phenotype.
Structural modeling. We employed the FoldX force field29 to model PR and GR in the binding pocket of 
transportin-1 (PDB code: 2OT8). In addition, we performed an unrestrained energy minimization using the 
YASARA2 force field to optimize the interactions between the PR/GR peptide and the binding pocket of trans-
portin 130. The graphical representation was generated using the Yasara program (version 13.2.21) where neg-
atively charged residues in the binding pocket, within a distance of 5 Angstrom of the peptide, were colored in 
blue.
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